$43,88
▼ $-0,16
(-0,36%)
Vol 1.7M
12
Skor Kualitas
ok
Pemeriksaan Mendalam
2/5
ok
Pendapatan ✓
Laba Bersih ✓
>IPO ✗
Kap. Pasar
$11.8B
P/E
17,3
ROE
31,6%
Margin
29,6%
D/E
0,00
Beta
0,42
52W
$32–$50
Konsensus Wall Street
27 analis · Apr 20266
Beli Kuat
9
Beli
11
Tahan
1
Jual
0
Jual Kuat
55,6%
Peringkat Beli
Grafik Harga
Saham Serupa
SMMT
Summit Therapeutics Inc
$13.0B
BBIO
BridgeBio Pharma Inc
$14.7B
NBIX
Neurocrine Biosciences Inc
P/E 33,0
$14.1B
MDGL
Madrigal Pharmaceuticals Inc
$13.2B
IONS
Ionis Pharmaceuticals Inc
$12.8B
BMRN
BioMarin Pharmaceutical Inc
P/E 21,9
$11.4B
PRAX
Praxis Precision Medicines Inc
$7.4B
ARWR
Arrowhead Pharmaceuticals Inc
$9.0B
PCVX
Vaxcyte Inc
$6.0B
Pendapatan
Tingkat beat: 100,0%
Laporan Berikutnya
Mei 11, 2026
Estimasi EPS: $0,73
| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Mar 2026 | $0,73 | — | — |
| Des 2025 | $0,82 | $0,88 | +$0,06 |
| Sep 2025 | $0,63 | $0,69 | +$0,06 |
| Jun 2025 | $0,57 | $0,65 | +$0,08 |
Tren Fundamental
| Metrik | 2025-07-04 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 27.7% | 27.7% | 27.7% | 27.7% | 31.6% | 31.6% |
| P/E (TTM) | 20.90 | 16.96 | 18.37 | 17.28 | 17.36 | 17.33 |
| Net Margin | 32.5% | 27.0% | 27.0% | 27.0% | 29.6% | 29.6% |
| Gross Margin | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% | 96.6% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.51 | 3.51 | 3.51 | 3.51 | 3.75 | 3.75 |
Rasio Utama
ROA (TTM)
24,0%
P/S (TTM)
5,14
P/B
4,3
EPS (TTM)
$2,38
CF/Share
$0,36
Pertumbuhan Pendapatan 3T
+10,4%
52W High
$49,62
52W Low
$31,90
$31,90
Rentang 52 Minggu
$49,62
Як EXEL виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка EXEL vs аналоги Biotechnology
P/E
17,3
▼
8%
di bawah
rekan
(18,8)
vs Rekan
vs Industri
Undervalued
P/S
5,1
▼
60%
di bawah
rekan
(12,9)
vs Rekan
vs Industri
Undervalued
P/B
4,3
▲
76%
di atas
rekan
(2,5)
vs Rekan
vs Industri
Overvalued
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,0%)
vs Rekan
vs Industri
Yield rendah
Прибутковість EXEL vs аналоги Biotechnology
ROE
31,6%
▲
147%
di atas
rekan
(-67,3%)
vs Rekan
vs Industri
Tingkat atas
Net margin
29,6%
▲
110%
di atas
rekan
(-286,8%)
vs Rekan
vs Industri
Di bawah rata-rata
Валова маржа
96,6%
▲
23%
di atas
rekan
(78,6%)
vs Rekan
vs Industri
Lemah
ROA
24,0%
▲
151%
di atas
rekan
(-46,7%)
vs Rekan
vs Industri
Tingkat atas
Фінансове здоровʼя EXEL vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
di bawah
rekan
(0,0)
vs Rekan
vs Industri
Utang rendah
Поточна ліквідність
3,8
▼
16%
di bawah
rekan
(4,4)
vs Rekan
vs Industri
Di bawah rata-rata
Beta
0,4
▼
57%
di bawah
rekan
(1,0)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів EXEL
EXEL
Median rekan
Industri
EXEL прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
EXEL vs аналоги: ключові метрики
Opini AI Terbaru
Grok
BUY
The price action shows a recent dip to a low of $39.71 on 2026-03-02 followed by a recovery to $41.41 close on 2026-03-23, positioning the current $41.37 as a solid entry point near support levels after volatility, with prior swings …
Mar 24, 2026